
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-04 15:38:54.556956
  Output will be saved to: test_outputs\workflow_test_20251204_153854.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 44 papers ---
  Full text (PMC): 21
  LLM verified: 44

  Diseases (35):
    - vitiligo: 3
    - adult-onset Still's disease: 3
    - atopic dermatitis: 3
    - juvenile idiopathic arthritis: 2
    - autoinflammatory interferonopathies: 2
    - systemic lupus erythematosus: 2
    - dermatomyositis, hidradenitis suppurativa, cutaneous lupus, cutaneous Crohn's disease: 1
    - dermatomyositis: 1
    - giant cell arteritis: 1
    - type I interferonopathies: 1
    - non-infectious uveitis: 1
    - folliculitis decalvans: 1
    - SAPHO syndrome: 1
    - polymyalgia rheumatica and giant cell arteritis: 1
    - dystrophic epidermolysis bullosa: 1

--- Sample Papers ---

  1. Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid...
     PMID: 38853646 | Disease: vitiligo
     Full text: False
     Why: Prospective case series with patient outcomes for steroid-resistant vitiligo...

  2. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Dis...
     PMID: 38051858 | Disease: dermatomyositis, hidradenitis suppurativa, cutaneous lupus, cutaneous Crohn's disease
     Full text: False
     Why: Case series with 6 patients showing efficacy outcomes across multiple inflammato...

  3. JAK inhibitors in refractory dermatomyositis: A case series....
     PMID: 38887110 | Disease: dermatomyositis
     Full text: False
     Why: Retrospective case series with 14 patients showing efficacy data for refractory ...

  4. Clinical experience and safety of Janus kinase inhibitors in giant cel...
     PMID: 37304255 | Disease: giant cell arteritis
     Full text: True
     Why: Retrospective case series with 15 patients showing efficacy data for giant cell ...

  5. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies:...
     PMID: 35418997 | Disease: type I interferonopathies
     Full text: True
     Why: Case series assessing efficacy and safety in type I interferonopathies patients...

--- Validation ---
  PASS: Found 44 papers
  WARN: 2 potentially irrelevant papers
    - Janus kinase inhibition for the treatment of refra...
    - Pharmacokinetics, Pharmacodynamics, and Proposed D...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 21 papers with PMC full text...
  (This may take several minutes)

  1. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant Cell Arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors showed significant reductions in inflammatory markers (CRP and ES...
     Safety: Two patients experienced serious infections but JAK inhibitor therapy was retain...

  2. [PMC] Janus Kinase Inhibitors in the Treatment of Type I Inte...
     WARN: No data extracted

  3. [PMC] Case report: Effectiveness of Janus kinase inhibitors i...
     PASS: Disease=isolated noninfectious uveitis, N=3, Response=100.0%
     Efficacy: All 3 patients with refractory isolated noninfectious uveitis achieved complete ...
     Safety: No significant side effects observed in any patients during mean follow-up of 31...

  4. [PMC] A Case Report of JAK Inhibitors Therapy for Adult-Onset...
     PASS: Disease=Adult-Onset Still's Disease, N=1, Response=100.0%
     Efficacy: JAK inhibitor therapy resulted in complete resolution of persistent pruritic les...
     Safety: Treatment was well-tolerated with only minor renal function abnormalities noted ...

  5. [PMC] Use of Baricitinib in a patient with treatment-resistan...
     PASS: Disease=pyoderma gangrenosum, N=1, Response=100.0%
     Efficacy: During 12 weeks of baricitinib treatment, the patient showed significant improve...
     Safety: Patient developed septic arthritis after discontinuing baricitinib, though tempo...

  6. [PMC] Janus kinase inhibition for the treatment of refractory...
     PASS: Disease=Frontal Fibrosing Alopecia, N=1, Response=100.0%
     Efficacy: Oral baricitinib 4 mg daily for 2 months resulted in complete resolution of infl...
     Safety: No adverse events were reported during the 2-month treatment course. Patient tol...

  7. [PMC] Mixed results with baricitinib in biological-resistant ...
     PASS: Disease=Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease, N=3, Response=67.0%
     Efficacy: Mixed results with baricitinib showing complete remission in 2 of 3 patients wit...
     Safety: One patient developed Pneumocystis jirovecii pneumonia at 7 months, representing...

  8. [PMC] Assessment of Clinical Response to Janus Kinase Inhibit...
     PASS: Disease=Familial chilblain lupus with TREX1 mutation, N=3, Response=100.0%
     Efficacy: All 3 patients showed significant improvement of cutaneous lupus lesions with su...
     Safety: No severe adverse reactions were reported during the 3-month treatment period. T...

  9. [PMC] Rheumatological complaints in H syndrome: from inflamma...
     PASS: Disease=H syndrome, N=1, Response=None%
     Efficacy: Baricitinib monotherapy provided only partial improvement in arthritis symptoms ...
     Safety: No adverse events were reported during the treatment period. The patient tolerat...

  10. [PMC] Off-label use of Baricitinib improves moderate and seve...
     PASS: Disease=moderate and severe atopic dermatitis, N=23, Response=None%
     Efficacy: Baricitinib demonstrated significant clinical improvement in moderate-to-severe ...
     Safety: No significant toxicities were reported during the 4-week treatment period. The ...

  11. [PMC] Baricitinib restrains the immune dysregulation in patie...
     WARN: No data extracted

  12. [PMC] Alopecia Areata Following the Use of Belimumab in a Pat...
     PASS: Disease=Systemic lupus erythematosus, N=1, Response=100.0%
     Efficacy: Patient showed significant improvement in alopecia universalis within 1 month of...
     Safety: No adverse events reported with baricitinib treatment. Patient was able to disco...

  13. [PMC] JAK1/2 inhibition with baricitinib in the treatment of ...
     PASS: Disease=Autoinflammatory interferonopathies (CANDLE, SAVI, and other interferonopathies), N=18, Response=67.0%
     Efficacy: Daily symptom scores significantly decreased (P < 0.0001) and corticosteroid dos...
     Safety: Most common adverse events were infections. One CANDLE patient discontinued due ...

  14. [PMC] Disease flares with baricitinib dose reductions and dev...
     PASS: Disease=CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome), N=10, Response=50.0%
     Efficacy: 50% of patients with CANDLE/PRAAS achieved lasting clinical remission on baricit...
     Safety: Higher baricitinib exposure required for CANDLE/PRAAS led to BK viral reactivati...

  15. [PMC] Sustained Interferon Signature Suppression With Anifrol...
     PASS: Disease=STING-Associated Vasculopathy with Onset in Infancy (SAVI), N=1, Response=None%
     Efficacy: Baricitinib alone provided insufficient control of interferon signaling and vasc...
     Safety: Baricitinib caused significant viral reactivations including BK viruria/viremia,...

  16. [PMC] Pharmacokinetics, Pharmacodynamics, and Proposed Dosing...
     PASS: Disease=Mendelian interferonopathies (CANDLE and SAVI), N=18, Response=None%
     Efficacy: Baricitinib demonstrated dose-dependent decreases in interferon biomarkers, conf...
     Safety: No specific adverse events were reported in this pharmacokinetic study. Safety d...

  17. [PMC] Combination of Baricitinib and Phototherapy in Adults W...
     PASS: Disease=vitiligo, N=49, Response=None%
     Efficacy: Baricitinib combined with narrowband UV-B phototherapy showed significant improv...
     Safety: Safety outcomes not detailed in the provided abstract....

  18. [PMC] Rapid response of lichen planus to baricitinib associat...
     PASS: Disease=cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: 83.3% of patients achieved treatment response with 50% or greater PGA score redu...
     Safety: 12 total adverse events occurred, with only one mild AE (neutropenia) deemed pro...

  19. [PMC] Efficacy and safety of baricitinib in Japanese patients...
     PASS: Disease=Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS), N=9, Response=None%
     Efficacy: Baricitinib demonstrated efficacy in NNS/CANDLE and SAVI patients with decreased...
     Safety: All patients experienced at least one treatment-emergent adverse event. Three pa...

  20. [PMC] Baricitinib for refractory Takayasu arteritis: a prospe...
     PASS: Disease=Takayasu arteritis, N=10, Response=60.0%
     Efficacy: Baricitinib achieved overall treatment response in 60% of refractory TAK patient...
     Safety: Treatment was well tolerated with only one patient discontinuing due to liver dy...

  21. [PMC] A retrospective study of the efficacy of JAK inhibitors...
     PASS: Disease=rheumatoid arthritis-interstitial lung disease (RA-ILD), N=31, Response=83.9%
     Efficacy: JAK inhibitors demonstrated efficacy in RA-ILD with 83.9% of patients showing st...
     Safety: No specific adverse events were reported in the study. Safety profile appears ac...

--- Validation ---
  Successful: 19/21

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 19 extractions...

  Fetching market intelligence for each disease...
  (This requires web search for epidemiology & standard of care)
  Market data fetched for 7/19 diseases

--- Scored Opportunities ---

  1. Giant Cell Arteritis
     Clinical:  7.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.0/10

  2. isolated noninfectious uveitis
     Clinical:  9.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    9.7/10 (25% weight)
     TOTAL:     8.8/10

  3. Adult-Onset Still's Disease
     Clinical:  9.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.6/10

  4. pyoderma gangrenosum
     Clinical:  8.5/10 (50% weight)
     Evidence:  4.7/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     7.6/10

  5. Frontal Fibrosing Alopecia
     Clinical:  9.5/10 (50% weight)
     Evidence:  4.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.0/10

  6. Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease
     Clinical:  7.5/10 (50% weight)
     Evidence:  7.3/10 (25% weight)
     Market:    8.7/10 (25% weight)
     TOTAL:     7.8/10

  7. Familial chilblain lupus with TREX1 mutation
     Clinical:  9.5/10 (50% weight)
     Evidence:  5.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.2/10

  8. H syndrome
     Clinical:  9.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.0/10 (25% weight)
     TOTAL:     8.2/10

  9. moderate and severe atopic dermatitis
     Clinical:  9.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.3/10

  10. Systemic lupus erythematosus
     Clinical:  9.5/10 (50% weight)
     Evidence:  5.3/10 (25% weight)
     Market:    9.7/10 (25% weight)
     TOTAL:     8.5/10

  11. Autoinflammatory interferonopathies (CANDLE, SAVI, and other interferonopathies)
     Clinical:  7.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.0/10

  12. CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome)
     Clinical:  4.5/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.0/10 (25% weight)
     TOTAL:     6.4/10

  13. STING-Associated Vasculopathy with Onset in Infancy (SAVI)
     Clinical:  3.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     5.3/10

  14. Mendelian interferonopathies (CANDLE and SAVI)
     Clinical:  5.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.6/10

  15. vitiligo
     Clinical:  7.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    10.0/10 (25% weight)
     TOTAL:     7.8/10

  16. cutaneous lichen planus
     Clinical:  9.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.4/10

  17. Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS)
     Clinical:  6.5/10 (50% weight)
     Evidence:  5.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.8/10

  18. Takayasu arteritis
     Clinical:  8.5/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.1/10

  19. rheumatoid arthritis-interstitial lung disease (RA-ILD)
     Clinical:  8.5/10 (50% weight)
     Evidence:  9.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.7/10

--- Validation ---
  Scored: 19/19

================================================================================
 TAB 5: FULL ANALYSIS SUMMARY
================================================================================

  Drug: baricitinib
  Mechanism: Janus Kinase Inhibitor
  Approved Indications: 4
  Papers Found: 44
  Papers with PMC Full Text: 21
  Extractions: 19

--- Top Off-Label Indications ---
    vitiligo: 3 papers
    adult-onset Still's disease: 3 papers
    atopic dermatitis: 3 papers
    juvenile idiopathic arthritis: 2 papers
    autoinflammatory interferonopathies: 2 papers
    systemic lupus erythematosus: 2 papers
    dermatomyositis, hidradenitis suppurativa, cutaneous lupus, cutaneous Crohn's disease: 1 papers
    dermatomyositis: 1 papers
    giant cell arteritis: 1 papers
    type I interferonopathies: 1 papers

--- Validation ---
  PASS: Full pipeline executed

================================================================================
 FINAL SUMMARY
================================================================================
  Tab 1 Drug Info:   PASS
  Tab 2 Search:      PASS (44 papers)
  Tab 3 Extraction:  PASS (19 successful)
  Tab 4 Scoring:     PASS (19 scored)
  Tab 5 Analysis:    PASS

  Total API Tokens: 179,590
  Completed: 2025-12-04 15:51:58.356715

  JSON data saved to: test_outputs\workflow_data_20251204_153854.json
